Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children42710.24287/1726-1708-2020-19-4-120-124CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯA case report of pilocytic astrocytoma of the brainstemСлучай пилоидной астроцитомы ствола головного мозгаhttps://orcid.org/0000-0002-5310-5928MerishavyanА. А.МеришавянА. А.
Russian Federation

Artur A. Merishavyan, a pediatric oncologist at the Hematology/Oncology Isolation Unit

1 Samory Mashela St., Moscow 117997

Меришавян Артур Арменович, врач-детский онколог боксированного отделения гематологии/онкологии

117997, Москва, ул. Саморы Машела, 1

merishavyan.artur@yandex.ruhttps://orcid.org/0000-0001-7750-5216PapushaL. I.ПапушаЛ. И.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-2977-665XValiakhmetovaE. F.ВалиахметоваЭ. Ф.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-1308-8622DruyA. E.ДруйА. Е.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-3007-3772YaskoL. A.ЯськоЛ. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-0079-7761BrilliantovaV. V.БриллиантоваВ. В.
Russian Federation

Moscow

Москва

ArtyomovA. V.АртемовА. В.
Russian Federation

Moscow

Москва

KarachunskyA. I.КарачунскийА. И.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России081220201941201242112202021122020Copyright ©; 2025, «D. Rogachev NMRCPHOI»Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2025«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/427

Low-grade gliomas (LGGs) of the brainstem are a rare nosological group among brain tumours in children. In most cases, radical resection of the tumours localized in the brainstem is impossible due to the high risk of postoperative neurological complications. Presently, there are no uniform approaches to the management of patients with residual tumours of the brainstem; furthermore, current LGG treatment protocols disregard molecular and genetic features of the tumour. In our article we describe the case of the patient with LGG of the brainstem after the performed biopsy. Despite the large volume of the tumour, we decided to follow the patient over time due to the following factors: verification of the “pilocytic astrocytoma” histological diagnosis, detection of the KIAA1549-BRAF chimeric transcript (a marker of a favourable prognosis), as well as the absence of neurological deficit. According to the neuroimaging data, the child has stable disease for a long period of time. The patients' parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

Глиомы низкой степени злокачественности (ГНСЗ) ствола головного мозга являются редкой нозологической группой среди опухолей головного мозга у детей. В большинстве случаев радикальное удаление опухолей данной локализации невыполнимо, поскольку связано с высоким риском развития послеоперационных неврологических осложнений. В настоящее время отсутствуют единые подходы к ведению пациентов с наличием остаточной опухоли ствола головного мозга. Кроме того, существующие протоколы лечения ГНСЗ не учитывают молекулярногенетические особенности опухоли. В данной статье описан случай пациентки с ГНСЗ ствола головного мозга после проведения биопсии. Верификация гистологического диагноза «пилоидная астроцитома», обнаружение химерного транскрипта KIAA1549-BRAF, являющегося маркером благоприятного прогноза, а также отсутствие неврологического дефицита позволило выбрать тактику динамического наблюдения, несмотря на значительный объем опухоли. У ребенка в течение длительного времени, по данным нейровизуализации, сохраняется стабилизация заболевания. Родители дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях.

low-grade gliomatumour of the brainstempilocytic astrocytomaKIAA1549-BRAF chimeric transcriptглиома низкой степени злокачественностиопухоль ствола головного мозгапилоидная астроцитомахимерный транскрипт KIAA1549-BRAF1. Robinson K.E. Fraley C.E., Pearson M.M, Kuttesch J.F., Compas B.E. Neurocognitive late effects of pediatric brain tumors of the posterior fossa: a quantitative review. J Int Neuropsychol Soc 2013; 19 (1): 44–53. DOI: 10.1017/S1355617712000987Robinson K.E. Fraley C.E., Pearson M.M, Kuttesch J.F., Compas B.E. Neurocognitive late effects of pediatric brain tumors of the posterior fossa: a quantitative review. J Int Neuropsychol Soc 2013; 19 (1): 44–53. DOI: 10.1017/S13556177120009872. Ostrom Q.T., Gittleman H., Ostrom Q.T., Gittleman H., Liao P., Rouse C., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007– 2011. Neuro Oncol 2014; 16: 1–63. DOI: 10.1093/neuonc/nou223Ostrom Q.T., Gittleman H., Ostrom Q.T., Gittleman H., Liao P., Rouse C., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007– 2011. Neuro Oncol 2014; 16: 1–63. DOI: 10.1093/neuonc/nou2233. Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., Ichimura K., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68 (21): 8673– 7. DOI: 10.1158/0008-5472.CAN-08-2097Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., Ichimura K., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68 (21): 8673– 7. DOI: 10.1158/0008-5472.CAN-08-20974. Korshunov A., Meyer J., Capper D., Christians A., Remke M., Witt H., et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118 (3): 401–5. DOI: 10.1007/s00401-009-0550-zKorshunov A., Meyer J., Capper D., Christians A., Remke M., Witt H., et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118 (3): 401–5. DOI: 10.1007/s00401-009-0550-z5. Dimitriadis E., Alexiou G.A., Tsotsou P., Simeonidi E., Stefanaki K., et al. BRAF alterations in pediatric low-grade gliomas and mixed neuronal–glial tumors. J Neuro Oncol 2013; 113 (3): 353–8. DOI: 10.1007/s11060-013-1131-5Dimitriadis E., Alexiou G.A., Tsotsou P., Simeonidi E., Stefanaki K., et al. BRAF alterations in pediatric low-grade gliomas and mixed neuronal–glial tumors. J Neuro Oncol 2013; 113 (3): 353–8. DOI: 10.1007/s11060-013-1131-56. Коновалов А.Н., Хухлаева Е.А., Гаврюшин А.В. Опухоли ствола головного мозга. Диагностика. Дифференцированный подход к лечению. Том II. М.: Современные технологии и клинические исследования в нейрохирургии; 2012. С. 123–139.Коновалов А.Н., Хухлаева Е.А., Гаврюшин А.В. Опухоли ствола головного мозга. Диагностика. Дифференцированный подход к лечению. Том II. М.: Современные технологии и клинические исследования в нейрохирургии; 2012. С. 123–139.7. Shibamoto Y., Takahashi M., Dokoh S., Tanabe M., Ishida T., Abe M. Radiation therapy for brain stem tumor with special reference to CT feature and prognosis correlations. Int J Radiat Oncol Biol Phys 1989; 17 (1): 71–6. DOI: 10.1016/0360-3016(89)90372-6Shibamoto Y., Takahashi M., Dokoh S., Tanabe M., Ishida T., Abe M. Radiation therapy for brain stem tumor with special reference to CT feature and prognosis correlations. Int J Radiat Oncol Biol Phys 1989; 17 (1): 71–6. DOI: 10.1016/0360-3016(89)90372-68. Epstein F., McCleary E. Intrinsic brainstem tumors of childhood: surgical indications. J Neurosurg 1986; 64 (1): 11–5. DOI: 10.3171/jns.1986.64.1.0011Epstein F., McCleary E. Intrinsic brainstem tumors of childhood: surgical indications. J Neurosurg 1986; 64 (1): 11–5. DOI: 10.3171/jns.1986.64.1.00119. Se-Yi C., Chien-Hua C., Ming-Hsi S., HsuTung L., Chiung-Chyi S. Stereotactic biopsy for brainstem lesion: Comparison of approachesand reports of 10 cases. J Chin Med Assoc 2010; 74 (3): 110–4. DOI: 10.1016/j.jcma.2011.01.024Se-Yi C., Chien-Hua C., Ming-Hsi S., HsuTung L., Chiung-Chyi S. Stereotactic biopsy for brainstem lesion: Comparison of approachesand reports of 10 cases. J Chin Med Assoc 2010; 74 (3): 110–4. DOI: 10.1016/j.jcma.2011.01.02410. Holzapfel J., Kandels D., Schmidt R., Pietsch T., Warmuth‐Metz M., Bison B., et al. Favorable prognosis in pediatric brainstem low‐grade glioma – report from the German SIOP‐LGG 2004 cohort. Int J Cancer 2019; 146 (12): 3385–96. DOI: 10.1002/ijc.32734Holzapfel J., Kandels D., Schmidt R., Pietsch T., Warmuth‐Metz M., Bison B., et al. Favorable prognosis in pediatric brainstem low‐grade glioma – report from the German SIOP‐LGG 2004 cohort. Int J Cancer 2019; 146 (12): 3385–96. DOI: 10.1002/ijc.3273411. Upadhyaya S.A., Koschmann C., Muraszko K., Venneti S., Garton H.J., Hamstra D.A., et al. Brainstem lowgrade gliomas in children – excellent outcomes with multimodality therapy. J Child Neurol 2017; 32 (2): 194–203. DOI: 10.1177/0883073816675547Upadhyaya S.A., Koschmann C., Muraszko K., Venneti S., Garton H.J., Hamstra D.A., et al. Brainstem lowgrade gliomas in children – excellent outcomes with multimodality therapy. J Child Neurol 2017; 32 (2): 194–203. DOI: 10.1177/088307381667554712. Lassaletta A., Zapotocky M., Mistry M., Ramaswamy V., Honnorat M., Krishnatry R., et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017; 35: 2934–41. DOI: 10.1200/jco.2016.34.15Lassaletta A., Zapotocky M., Mistry M., Ramaswamy V., Honnorat M., Krishnatry R., et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017; 35: 2934–41. DOI: 10.1200/jco.2016.34.1513. Hawkins C., Walker E., Mohamed N., Zhang C., Jacob K., Shirinian M., et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011; 17: 4790–8. DOI: 10.1158/1078-0432.CCR-11-0034Hawkins C., Walker E., Mohamed N., Zhang C., Jacob K., Shirinian M., et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011; 17: 4790–8. DOI: 10.1158/1078-0432.CCR-11-003414. Horbinski C., Nikiforova M.N., Hagenkord J.M., Hamilton R.L., Pollack I.F. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012; 14: 777–89. DOI: 10.1093/neuonc/nos077Horbinski C., Nikiforova M.N., Hagenkord J.M., Hamilton R.L., Pollack I.F. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012; 14: 777–89. DOI: 10.1093/neuonc/nos07715. Banerjee A., Jakacki R.I., Onar-Thomas A., Wu S., Nicolaides T., Young Poussaint T., et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory lowgrade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 2017; 19 (8): 1135–44. DOI: 10.1093/neuonc/now282Banerjee A., Jakacki R.I., Onar-Thomas A., Wu S., Nicolaides T., Young Poussaint T., et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory lowgrade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 2017; 19 (8): 1135–44. DOI: 10.1093/neuonc/now28216. Bouffet E., Kieran M., Hargrave D., Roberts S., Aerts I., Broniscer A., et al. Trametinib therapy in pediatric patients with low-grade gliomas (LGG) with BRAF gene fusion; a disease-specific cohort in the first pediatric testing of trametinib. Neuro Oncol 2018; 20: 114. DOI: 10.1093/neuonc/noy059.387Bouffet E., Kieran M., Hargrave D., Roberts S., Aerts I., Broniscer A., et al. Trametinib therapy in pediatric patients with low-grade gliomas (LGG) with BRAF gene fusion; a disease-specific cohort in the first pediatric testing of trametinib. Neuro Oncol 2018; 20: 114. DOI: 10.1093/neuonc/noy059.38717. Lassaletta A., Guerreiro Stucklin A., Ramaswamy V., Zapotocky M., McKeown T., Hawkins C., et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer 2016; 63 (11): 2038–41. DOI: 10.1002/pbc.26086Lassaletta A., Guerreiro Stucklin A., Ramaswamy V., Zapotocky M., McKeown T., Hawkins C., et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer 2016; 63 (11): 2038–41. DOI: 10.1002/pbc.2608618. Del Bufalo F., Ceglie G., Cacchione A., Alessi I., Colafati G.S., Carai A., et al. BRAFV600E inhibitor (vemurafenib) for BRAF V600E mutated low grade gliomas. Front Oncol 2018; 8: 526. DOI: 10.3389/fonc.2018.00526Del Bufalo F., Ceglie G., Cacchione A., Alessi I., Colafati G.S., Carai A., et al. BRAFV600E inhibitor (vemurafenib) for BRAF V600E mutated low grade gliomas. Front Oncol 2018; 8: 526. DOI: 10.3389/fonc.2018.00526